Literature DB >> 3880961

HNK-1+ (Leu-7) and other lymphocyte subsets in long-term survivors with renal allotransplants.

I Fregona, R D Guttmann, R Jean.   

Abstract

At 5 or more years after renal transplantation, 42 patients were studied for their lymphocyte subsets to Leu-1, Leu-2, Leu-3, and Leu-7. It was found that, in this group of patients who ranged from 25 to 60 years of age, there was a significant decrease in the number of T helper cells and a decrease in the absolute level of T lymphocytes, with no significant change in the number of T suppressor cells. On a relative basis, the helper/suppressor ratio was decreased in patients when compared with normal persons. This was due to an increase in the relative numbers of suppressor cells. It was demonstrated that the Leu-7+ subset, which marks the NK population, was significantly elevated, in relative proportion, in peripheral blood when compared with controls. This was not seen on an absolute basis. The age-dependence of the relative numbers of Leu-7+ cells was seen in the normal control population and in the transplant cohort. There was no significant correlation between lymphocyte subset measurements and delayed-type hypersensitivity skin tests in the transplant population. A finding of interest is that 6 of the patients who had been treated for malignant disease during their posttransplant course had significantly higher numbers of Leu-7+ cells on a relative basis. In 5 of these patients, for whom data was available on absolute numbers, there was also a highly significant difference in the absolute numbers of Leu-7+ cells in these treated and surviving allograft recipients. It is speculated that this finding may suggest that an increase in Leu-7+ cells marks posttransplant patients who have a successful outcome following the treatment of malignancy, for which they are at increased risk.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3880961

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

1.  CD3+ CD57+ lymphocytes are not likely to be involved in antigen-specific rejection processes in long-term allograft recipients.

Authors:  B Reipert; C Scheuch; A Lukowsky; P Reinke; E Fietze; W D Döcke; G Staffa; S Czerlinksi; R Hetzer; H D Volk
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

2.  Increase of CD57+ T cells in knee joints and adjacent bone marrow of rheumatoid arthritis (RA) patients: implication for an anti-inflammatory role.

Authors:  K Arai; S Yamamura; S Seki; T Hanyu; H E Takahashi; T Abo
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

3.  Changes in natural killer cells, the CD57CD8 subset, and related cytokines in healthy aging.

Authors:  S E McNerlan; I M Rea; H D Alexander; T C Morris
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

4.  Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis.

Authors:  Masanobu Tsuda; Yoko M Ambrosini; Weici Zhang; Guo-Xiang Yang; Yugo Ando; Guanghua Rong; Koichi Tsuneyama; Kosuke Sumida; Shinji Shimoda; Christopher L Bowlus; Patrick S C Leung; Xiao-Song He; Ross L Coppel; Aftab A Ansari; Zhe-Xiong Lian; M Eric Gershwin
Journal:  Hepatology       Date:  2011-10       Impact factor: 17.425

5.  Analysis of the susceptibility of CD57 T cells to CD3-mediated apoptosis.

Authors:  N Shinomiya; Y Koike; H Koyama; E Takayama; Y Habu; M Fukasawa; S Tanuma; S Seki
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

6.  CD57+ T cells augment IFN-gamma production in a one-way mixed lymphocyte reaction and their expansion after stem cell transplantation in paediatric patients.

Authors:  Y Koike; S Seki; T Ohkawa; T Kaneko; K Kogawa; S Fujitsuka; H Hiraide; I Sekine
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

7.  Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.

Authors:  T Ohkawa; S Seki; H Dobashi; Y Koike; Y Habu; K Ami; H Hiraide; I Sekine
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

8.  PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients.

Authors:  Junji Akagi; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2010-03-13       Impact factor: 3.402

9.  Subsets of CD8+, CD57+ cells in normal, healthy individuals: correlations with human cytomegalovirus (HCMV) carrier status, phenotypic and functional analyses.

Authors:  E C Wang; J Taylor-Wiedeman; P Perera; J Fisher; L K Borysiewicz
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

10.  Prognostic value of CD57(+) T lymphocytes in the peripheral blood of patients with advanced gastric cancer.

Authors:  Junji Akagi; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.